Study of some herbal formulations in the management of Computer Vision Syndrome

Phase 2

Completed

• Conditions: Health Condition 1: null- Computer Vision Syndrome

• Registration Number: CTRI/2017/08/009518
• Lead Sponsor: Centrral Council for Research in Ayurvedic Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2016-12-05
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 62

Inclusion Criteria

i)Patients of either sex aged between 18 to 35 years

ii)Patients having minimum three symptoms of Computer Vision Syndrome (Eye strain and fatigue,Headache, blurred vision, Dry and irritated eyes, Neck and shoulder pain, Double vision,Redness of eyes, Burning eyes, excessive tearing and photophobia)

iii)Minimum 3 hours daily exposure to any type of Video Display Terminals like Desktop, Laptop or both

iv)Minimum 1 year exposure to any type of above mentioned VDTs

v)Willing patients with informed consent obtained.

Exclusion Criteria

i)Age less than 18 years and more than 35 years

ii)Presence of signs and symptoms due to direct physiological effects of substance (medication, drug abuse) or presence of any general health problems (like Hypothyroidism)

iii)Presence of any infectious conditions of the eye, Cataract, Glaucoma, stye, any fundus pathology.

iv)Patients having Cervical spondylosis or spasm of trapezius muscle.

v)History of any surgical intervention with reference to the eye

vi)Patient with h/o Migraine

vii)Patients with h/o Hypertension or Diabetes Mellitus

viii)Patients with evidence of malignancy.

ix)Patients on prolonged ( 6 weeks) medication withcorticosteroids, antidepressants, anticholinergics, oral Contraceptive pills, etc.or any other drugs that may have an influence on the outcome of the study.

x)Patients with major systemic illness

xi)Patients with concurrent serious hepatic disorder defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine1.2mg/dL), Known case of Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]),

or any other condition that may jeopardize the study.

xii)Smokers/ Alcoholics and/or drug abuser

xiii)H/o hypersensitivity to any of the trial drug or their ingredients

xiv)Pregnant / lactating woman.

xv) Patients who have completed participation in any other

clinical trial during the past six (06) months

xvi) Any other condition which the Principal Investigator thinks may jeopardize the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified